AU2019230220B2 - Methods of use and pharmaceutical compositions of a selective Syk inhibitor - Google Patents

Methods of use and pharmaceutical compositions of a selective Syk inhibitor Download PDF

Info

Publication number
AU2019230220B2
AU2019230220B2 AU2019230220A AU2019230220A AU2019230220B2 AU 2019230220 B2 AU2019230220 B2 AU 2019230220B2 AU 2019230220 A AU2019230220 A AU 2019230220A AU 2019230220 A AU2019230220 A AU 2019230220A AU 2019230220 B2 AU2019230220 B2 AU 2019230220B2
Authority
AU
Australia
Prior art keywords
compound
composition
eye
aqueous ophthalmic
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019230220A
Other languages
English (en)
Other versions
AU2019230220A1 (en
Inventor
Mark Abelson
Matthew CHAPIN
Yung Yueh HSU
Anjali Pandey
Harold PATTERSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Ora Inc
Original Assignee
Alexion Pharmaceuticals Inc
Ora Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc, Ora Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2019230220A1 publication Critical patent/AU2019230220A1/en
Assigned to ALEXION PHARMACEUTICALS, INC., ORA, INC. reassignment ALEXION PHARMACEUTICALS, INC. Request for Assignment Assignors: ORA, INC., PORTOLA PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2019230220B2 publication Critical patent/AU2019230220B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019230220A 2018-03-09 2019-03-08 Methods of use and pharmaceutical compositions of a selective Syk inhibitor Active AU2019230220B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862641094P 2018-03-09 2018-03-09
US62/641,094 2018-03-09
US201862663999P 2018-04-27 2018-04-27
US62/663,999 2018-04-27
PCT/US2019/021402 WO2019173744A1 (en) 2018-03-09 2019-03-08 Methods of use and pharmaceutical compositions of a selective syk inhibitor

Publications (2)

Publication Number Publication Date
AU2019230220A1 AU2019230220A1 (en) 2020-10-08
AU2019230220B2 true AU2019230220B2 (en) 2025-01-30

Family

ID=65818744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019230220A Active AU2019230220B2 (en) 2018-03-09 2019-03-08 Methods of use and pharmaceutical compositions of a selective Syk inhibitor

Country Status (15)

Country Link
US (1) US20210052582A1 (https=)
EP (1) EP3761986A1 (https=)
JP (1) JP7417531B2 (https=)
KR (1) KR20210018193A (https=)
CN (2) CN112243375A (https=)
AU (1) AU2019230220B2 (https=)
BR (1) BR112020018377A2 (https=)
CA (1) CA3093371A1 (https=)
IL (1) IL277093A (https=)
MX (1) MX2020009396A (https=)
PH (1) PH12020551418A1 (https=)
SG (1) SG11202008765UA (https=)
TW (1) TWI805705B (https=)
WO (1) WO2019173744A1 (https=)
ZA (1) ZA202005459B (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009136995A2 (en) * 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
US8318755B2 (en) * 2008-04-16 2012-11-27 Portola Pharmaceuticals, Inc. Inhibitors of SYK and JAK protein kinases
US20130274216A1 (en) * 2012-04-12 2013-10-17 Alcon Research, Ltd. Treatment for microbe-induced inflammatory responses in the eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
KR101454674B1 (ko) 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
KR20140103168A (ko) * 2011-12-16 2014-08-25 알러간, 인코포레이티드 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물
EP2897950A1 (en) * 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009136995A2 (en) * 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
US8318755B2 (en) * 2008-04-16 2012-11-27 Portola Pharmaceuticals, Inc. Inhibitors of SYK and JAK protein kinases
US20130274216A1 (en) * 2012-04-12 2013-10-17 Alcon Research, Ltd. Treatment for microbe-induced inflammatory responses in the eye

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS:"Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis", 25 Oct 2017, Retrieved from Internet *
GARY D. NOVACK: "Eyes on New Product Development", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS., vol. 31, no. 6, 1 July 2015 (2015-07-01), US, pages 311 - 313, XP055593402, ISSN: 1080-7683, DOI: 10.1089/jop.2015.29000.gdn *

Also Published As

Publication number Publication date
SG11202008765UA (en) 2020-10-29
US20210052582A1 (en) 2021-02-25
TWI805705B (zh) 2023-06-21
AU2019230220A1 (en) 2020-10-08
KR20210018193A (ko) 2021-02-17
PH12020551418A1 (en) 2021-09-01
MX2020009396A (es) 2021-01-15
IL277093A (en) 2020-10-29
BR112020018377A2 (pt) 2021-03-09
CN119235862A (zh) 2025-01-03
JP2021517139A (ja) 2021-07-15
CA3093371A1 (en) 2019-09-12
EP3761986A1 (en) 2021-01-13
JP7417531B2 (ja) 2024-01-18
WO2019173744A1 (en) 2019-09-12
CN112243375A (zh) 2021-01-19
ZA202005459B (en) 2023-02-22
TW202002980A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
CN1753683B (zh) 预防和治疗不良眼部病症的眼用制剂
JP7505786B2 (ja) ドライアイ疾患を処置するための製剤
KR100889170B1 (ko) 안구 건조의 치료에 있어서 리멕솔론의 용도
US20210177807A1 (en) Compositions for the treatment and prevention of eyelid swelling
TWI650122B (zh) 用於預防及／或治療乾眼症之組成物、方法及／或裝置
US20090010850A1 (en) Formulations and methods for treating dry eye
WO2009061431A2 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2007127333A2 (en) Compositions for the treatment and prevention of eyelid swelling
US20050239745A1 (en) Novel topical ophthalmic formulations
Sarmento et al. Can (Natural) deep eutectic systems increase the efficacy of ocular therapeutics?
CN116437910A (zh) 含有西替利嗪和托可索仑的眼用组合物
AU2019230220B2 (en) Methods of use and pharmaceutical compositions of a selective Syk inhibitor
KR20240050324A (ko) 빈포세틴을 사용한 근시치료방법
Bandyopadhyay et al. Development of ophthalmic formulations
Gibson 12 Ophthalmic dosage forms
CN103202833A (zh) 一种奥洛他定或其盐的药用组合物及其制备方法
JPH06511014A (ja) 眼への投与に用いる、緩衝剤系を含有するベラパミル塩酸製剤などの眼科用液剤

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ORA, INC.

Free format text: FORMER APPLICANT(S): ORA, INC.; PORTOLA PHARMACEUTICALS, INC.

Owner name: ALEXION PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): ORA, INC.; PORTOLA PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)